Cargando…

Association of HLA-DQ Heterodimer Residues −18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1

OBJECTIVE: The purpose was to test the hypothesis that the HLA-DQαβ heterodimer structure is related to the progression of islet autoimmunity from asymptomatic to symptomatic type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Next-generation targeted sequencing was used to genotype HLA-DQA1-B1 clas...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lue Ping, Skyler, Jay, Papadopoulos, George K., Pugliese, Alberto, Najera, James Antonio, Bondinas, George P., Moustakas, Antonis K., Wang, Ruihan, Pyo, Chul-Woo, Nelson, Wyatt C., Geraghty, Daniel E., Lernmark, Åke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274226/
https://www.ncbi.nlm.nih.gov/pubmed/35621697
http://dx.doi.org/10.2337/dc21-1628
_version_ 1784745260814958592
author Zhao, Lue Ping
Skyler, Jay
Papadopoulos, George K.
Pugliese, Alberto
Najera, James Antonio
Bondinas, George P.
Moustakas, Antonis K.
Wang, Ruihan
Pyo, Chul-Woo
Nelson, Wyatt C.
Geraghty, Daniel E.
Lernmark, Åke
author_facet Zhao, Lue Ping
Skyler, Jay
Papadopoulos, George K.
Pugliese, Alberto
Najera, James Antonio
Bondinas, George P.
Moustakas, Antonis K.
Wang, Ruihan
Pyo, Chul-Woo
Nelson, Wyatt C.
Geraghty, Daniel E.
Lernmark, Åke
author_sort Zhao, Lue Ping
collection PubMed
description OBJECTIVE: The purpose was to test the hypothesis that the HLA-DQαβ heterodimer structure is related to the progression of islet autoimmunity from asymptomatic to symptomatic type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Next-generation targeted sequencing was used to genotype HLA-DQA1-B1 class II genes in 670 subjects in the Diabetes Prevention Trial–Type 1 (DPT-1). Coding sequences were translated into DQ α- and β-chain amino acid residues and used in hierarchically organized haplotype (HOH) association analysis to identify motifs associated with diabetes onset. RESULTS: The opposite diabetes risks were confirmed for HLA DQA1*03:01-B1*03:02 (hazard ratio [HR] 1.36; P = 2.01 ∗ 10(−3)) and DQA1*03:03-B1*03:01 (HR 0.62; P = 0.037). The HOH analysis uncovered residue −18β in the signal peptide and β57 in the β-chain to form six motifs. DQ*VA was associated with faster (HR 1.49; P = 6.36 ∗ 10(−4)) and DQ*AD with slower (HR 0.64; P = 0.020) progression to diabetes onset. VA/VA, representing DQA1*03:01-B1*03:02 (DQ8/8), had a greater HR of 1.98 (P = 2.80 ∗ 10(−3)). The DQ*VA motif was associated with both islet cell antibodies (P = 0.023) and insulin autoantibodies (IAAs) (P = 3.34 ∗ 10(−3)), while the DQ*AD motif was associated with a decreased IAA frequency (P = 0.015). Subjects with DQ*VA and DQ*AD experienced, respectively, increasing and decreasing trends of HbA(1c) levels throughout the follow-up. CONCLUSIONS: HLA-DQ structural motifs appear to modulate progression from islet autoimmunity to diabetes among at-risk relatives with islet autoantibodies. Residue −18β within the signal peptide may be related to levels of protein synthesis and β57 to stability of the peptide-DQab trimolecular complex.
format Online
Article
Text
id pubmed-9274226
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-92742262022-07-28 Association of HLA-DQ Heterodimer Residues −18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1 Zhao, Lue Ping Skyler, Jay Papadopoulos, George K. Pugliese, Alberto Najera, James Antonio Bondinas, George P. Moustakas, Antonis K. Wang, Ruihan Pyo, Chul-Woo Nelson, Wyatt C. Geraghty, Daniel E. Lernmark, Åke Diabetes Care Pathophysiology/Complications OBJECTIVE: The purpose was to test the hypothesis that the HLA-DQαβ heterodimer structure is related to the progression of islet autoimmunity from asymptomatic to symptomatic type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: Next-generation targeted sequencing was used to genotype HLA-DQA1-B1 class II genes in 670 subjects in the Diabetes Prevention Trial–Type 1 (DPT-1). Coding sequences were translated into DQ α- and β-chain amino acid residues and used in hierarchically organized haplotype (HOH) association analysis to identify motifs associated with diabetes onset. RESULTS: The opposite diabetes risks were confirmed for HLA DQA1*03:01-B1*03:02 (hazard ratio [HR] 1.36; P = 2.01 ∗ 10(−3)) and DQA1*03:03-B1*03:01 (HR 0.62; P = 0.037). The HOH analysis uncovered residue −18β in the signal peptide and β57 in the β-chain to form six motifs. DQ*VA was associated with faster (HR 1.49; P = 6.36 ∗ 10(−4)) and DQ*AD with slower (HR 0.64; P = 0.020) progression to diabetes onset. VA/VA, representing DQA1*03:01-B1*03:02 (DQ8/8), had a greater HR of 1.98 (P = 2.80 ∗ 10(−3)). The DQ*VA motif was associated with both islet cell antibodies (P = 0.023) and insulin autoantibodies (IAAs) (P = 3.34 ∗ 10(−3)), while the DQ*AD motif was associated with a decreased IAA frequency (P = 0.015). Subjects with DQ*VA and DQ*AD experienced, respectively, increasing and decreasing trends of HbA(1c) levels throughout the follow-up. CONCLUSIONS: HLA-DQ structural motifs appear to modulate progression from islet autoimmunity to diabetes among at-risk relatives with islet autoantibodies. Residue −18β within the signal peptide may be related to levels of protein synthesis and β57 to stability of the peptide-DQab trimolecular complex. American Diabetes Association 2022-07-07 2022-05-27 /pmc/articles/PMC9274226/ /pubmed/35621697 http://dx.doi.org/10.2337/dc21-1628 Text en © 2022 by the American Diabetes Association https://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
spellingShingle Pathophysiology/Complications
Zhao, Lue Ping
Skyler, Jay
Papadopoulos, George K.
Pugliese, Alberto
Najera, James Antonio
Bondinas, George P.
Moustakas, Antonis K.
Wang, Ruihan
Pyo, Chul-Woo
Nelson, Wyatt C.
Geraghty, Daniel E.
Lernmark, Åke
Association of HLA-DQ Heterodimer Residues −18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1
title Association of HLA-DQ Heterodimer Residues −18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1
title_full Association of HLA-DQ Heterodimer Residues −18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1
title_fullStr Association of HLA-DQ Heterodimer Residues −18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1
title_full_unstemmed Association of HLA-DQ Heterodimer Residues −18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1
title_short Association of HLA-DQ Heterodimer Residues −18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1
title_sort association of hla-dq heterodimer residues −18β and β57 with progression from islet autoimmunity to diabetes in the diabetes prevention trial–type 1
topic Pathophysiology/Complications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274226/
https://www.ncbi.nlm.nih.gov/pubmed/35621697
http://dx.doi.org/10.2337/dc21-1628
work_keys_str_mv AT zhaolueping associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT skylerjay associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT papadopoulosgeorgek associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT pugliesealberto associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT najerajamesantonio associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT bondinasgeorgep associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT moustakasantonisk associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT wangruihan associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT pyochulwoo associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT nelsonwyattc associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT geraghtydaniele associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1
AT lernmarkake associationofhladqheterodimerresidues18bandb57withprogressionfromisletautoimmunitytodiabetesinthediabetespreventiontrialtype1